Company profile
Home - Badrilla
Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.
Financial period: 1 Jul 2023 to 30 Jun 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUxMjczMjMxM2FkaXF6a2N4
Published 26 Mar 2026 09:57
Last accounts made up date
Last confirmation statement made up date
AD01 | Transaction MzQzNzk0NTQzMGFkaXF6a2N4
Published 01 Oct 2024 10:59
Company registered at Companies House
1 Feb 2018 to 31 Jan 2020
To introduce and embed a new quantitative biomarker detection technique and develop products and services using this technology to enhance biomedical research and accelerate drug development by collaborators.
1 Dec 2014 to 30 Jun 2015
Acute kidney injury (AKI) causes 12,000 preventable deaths per year in England. It affects 14% of people admitted to hospital, extending their hospital stay 2.5fold (£1.2Bn cost per annum to NHS England) and increasing their chance of death 4-5fold. Better diagnostics are required to identify AKI patients early. This will permit the focusing of resources ...
1 Aug 2014 to 30 Nov 2014
An emerging class of biomarkers important in medical diagnostics for cancer, dementia and cardiovascular disease is the chemical modification state of individual proteins. Quantitative diagnostic assays for these particular features of proteins are not available, and Badrilla proposes to develop an entirely new approach that will achieve such quantitative...
